|SetPoint is developing breakthrough therapies to reduce systemic inflammation by stimulating the vagus nerve using an implantable pulse generator. This activates the body's natural Inflammatory Reflex and is intended to dampen inflammation to improve clinical signs and symptoms.
First-in-Human Pilot Study Validates Neuromodulation Approach
SetPoint Medical announced positive results from the first-ever human study using an implanted neuromodulation device to treat rheumatoid arthritis at the American College of Rheumatology Annual Meeting in November 2012.
The results of this open-label pilot study confirm extensive preclinical studies and suggest efficacy with neuromodulation. The results are similar to those typically achieved in larger studies with drugs currently used to treat RA. At the primary end point, using the Disease Activity Score (DAS) and the American College of Rheumatology Response Rate (ACR), both standard RA efficacy measures for RA, two of the eight patients in the study achieved DAS remission, and six of the eight had a positive ACR 20 response.
The SetPoint Platform
SetPoint's proprietary neuromodulation platform consists of an implantable microregulator, wireless charger and iPad prescription pad application.
SetPoint is using its neuromodulation platform to develop safe and effective alternative therapies to target other diseases.
CAUTION: Investigational device in the US and the European Union. Limited by country law to investigational use only.